Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
80Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-15.80M | $-10.63 |
| 2024 | $0.00 | $-8.96M | $-66.85 |
| 2023 | $0.00 | $-8.69M | $-337.47 |
| 2022 | $0.00 | $-9.38M | $-22.97 |
| 2021 | $0.00 | $-21.46M | $-28543.20 |
Social Signal Score
Earnings
Thu, Nov 5(in 3 months)
Consensus estimate $-1.88 per share
Typical surprise -18.0% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Aug 14$-1.90 vs $-1.61miss
- Thu, May 7$-1.77 vs $-1.80beat
- Thu, Mar 26$-14.80 vs $-6.42miss
- Thu, Nov 6$-6.71 vs $-6.36miss
- Thu, Aug 7$-6.28 vs $-6.83beat
- Tue, May 13$-6.50 vs $-3.85miss
Estimates and results for QNRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
QNRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (1)
- Newsglobenewswire.com·1d ago·Negative
Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results – Receives FDA Conditional Approval of QYLEKI™ as the Proposed Brand Name for QRX003 for Netherton Syndrome – Reports Positive Clinical Update from Ongoing Pediatric Compassionate Use Program in Netherton Syndrome – Receives U.S. Notice of Allowance for a Patent Covering a Combination Treatment for Netherton Syndrome – Submits First-Ever IND for Peeling Skin Syndrome; FDA Clearance Received Subseque
View source ↗